ArticleInternational journal of pharmaceutics: X2024
Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells.
Article in International journal of pharmaceutics: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Quantum dot enhanced photonic biosensors for single cell analysis from synthesis to clinical application.Discover nano · 2026Review
- Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.Current pharmaceutical design · 2026Review
- Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells.International journal of pharmaceutics: X · 2025Article
- Breast Cancer Progression and Its Theranostic Management via Folate-Directed Targeting of Glycoprotein Receptor.Medical sciences (Basel, Switzerland) · 2025Review
- Mucoadhesive Carbohydrate-Based Polymeric Nanocapsule Loaded with Palbociclib for Enhanced GIT Retention and In Vitro Anticancer Efficacy in MDA-MB-231 Cells.AAPS PharmSciTech · 2025Article
- Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Niosome Preparation Techniques and Structure-An Illustrated Review.Pharmaceutics · 2025Review
- Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations.Oncology research · 2025Review
- Quantum Dot Research in Breast Cancer: Challenges and Prospects.Materials (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we present a targeted and pH-sensitive niosomal (pHSN) formulation, incorporating quantum dot (QD)-labeled Trastuzumab (Trz) molecules for the specific delivery of Palbociclib (Pal) to cells overexpressing human epidermal growth factor receptor 2 (HER2). FTIR analyses confirmed the successful preparation of the pHSNs and their bioconjugation. The labeled Trz-conjugated Pal-pHSNs (Trz-Pal-pHSNs) exhibited a size of approximately 170 nm, displaying a spherical shape with a neutral surface charge of -1.2 mV. Pal encapsulation reached ∼86%, and the release pattern followed a two-phase pH-dependent mechanism. MTT assessments demonstrated enhanced apoptosis induction, particularly in HER2-positive cells, by Trz-Pal-pHSNs. Fluorescence imaging further validated the internalization of particles into cells. In conclusion, Trz-Pal-pHSNs emerge as a promising platform for personalized medicine in the treatment of HER2-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.